钆基纳米颗粒增强卵巢癌腹膜转移对靶向放射治疗的敏感性
该研究在卵巢癌腹膜癌小鼠模型中探讨钆基纳米颗粒(Gd-NPs)能否增强[177Lu]Lu-DOTA-曲妥珠单抗的靶向放射治疗疗效。结果显示,在注射5 MBq [177Lu]Lu-DOTA-曲妥珠单抗后24和72小时给予两次5 mg Gd-NPs(间隔6小时)时肿瘤质量减少最显著;体外实验提示Gd-NPs的放射增敏效应由氧化应激介导,并可被去铁酮抑制。作者认为该联合方案可提高疗效并降低注射活度,可能成为卵巢腹膜癌患者的新治疗途径。
要点
- 在HER2阳性卵巢癌腹膜移植瘤小鼠中,与Gd-NPs联合时[177Lu]Lu-DOTA-曲妥珠单抗的最佳活度为5 MBq。
- 注射5 MBq [177Lu]Lu-DOTA-曲妥珠单抗后24和72小时给予两次5 mg Gd-NPs(间隔6小时)时肿瘤质量减少最显著。
- 体外实验显示Gd-NPs与溶酶体共定位,其放射增敏效应由氧化应激介导并可被去铁酮抑制。
核心结论
- 靶向放射治疗可与Gd-NPs联合以增强治疗效果并降低注射活度。
- 由于Gd-NPs已用于临床,该联合方案可能成为卵巢腹膜癌患者的新治疗途径。
研究设计与样本
- 研究在荷人表皮生长因子受体2阳性卵巢癌细胞腹腔移植瘤的无胸腺小鼠中开展。
- 首先比较[177Lu]Lu-DOTA-曲妥珠单抗10、5、2.5 MBq单用或联合单次10 mg Gd-NPs的疗效以确定最佳活度。
- 随后评估5 MBq [177Lu]Lu-DOTA-曲妥珠单抗联合Gd-NPs(3种给药方案)的疗效与毒性,对照为NaCl、曲妥珠单抗加Gd-NPs及单用[177Lu]Lu-DOTA-曲妥珠单抗。
- 研究进行了生物分布与剂量测定,并开展能量沉积的蒙特卡罗模拟。
- 最后在3种癌细胞系中研究Gd-NPs的亚细胞定位、摄取及联合方案的细胞毒性效应以探索机制。
主要发现
- 与Gd-NPs联合时[177Lu]Lu-DOTA-曲妥珠单抗的最佳活度为5 MBq。
- 与单用[177Lu]Lu-DOTA-曲妥珠单抗相比,在注射5 MBq [177Lu]Lu-DOTA-曲妥珠单抗后24和72小时给予两次5 mg Gd-NPs(间隔6小时)时肿瘤质量减少最显著。
- 体外实验显示Gd-NPs与溶酶体共定位,其放射增敏效应由氧化应激介导并可被铁螯合剂去铁酮抑制。
- Gd-NPs暴露于177Lu后俄歇电子产额增加,但吸收剂量未增加。
关键数值与推荐
- 与Gd-NPs联合时[177Lu]Lu-DOTA-曲妥珠单抗的最佳活度为5 MBq。
- 最强疗效方案为注射5 MBq [177Lu]Lu-DOTA-曲妥珠单抗后24和72小时给予两次5 mg Gd-NPs(间隔6小时)。
- Gd-NPs的放射增敏效应可被去铁酮抑制。
- Gd-NPs暴露于177Lu后俄歇电子产额增加但吸收剂量未增加。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ovarian cancer (OC) is the most lethal gynecologic malignancy (5-y overall survival rate, 46%). OC is generally detected when it has already spread to the peritoneal cavity (peritoneal carcinomatosis). This study investigated whether gadolinium-based nanoparticles (Gd-NPs) increase the efficacy of targeted radionuclide therapy using [177Lu]Lu-DOTA-trastuzumab (an antibody against human epidermal growth factor receptor 2). Gd-NPs have radiosensitizing effects in conventional external-beam radiotherapy and have been tested in clinical phase II trials. Methods: First, the optimal activity of [177Lu]Lu-DOTA-trastuzumab (10, 5, or 2.5 MBq) combined or not with 10 mg of Gd-NPs (single injection) was investigated in athymic mice bearing intraperitoneal OC cell (human epidermal growth factor receptor 2-positive) tumor xenografts. Next, the therapeutic efficacy and toxicity of 5 MBq of [177Lu]Lu-DOTA-trastuzumab with Gd-NPs (3 administration regimens) were evaluated. NaCl, trastuzumab plus Gd-NPs, and [177Lu]Lu-DOTA-trastuzumab alone were used as controls. Biodistribution and dosimetry were determined, and Monte Carlo simulation of energy deposits was performed. Lastly, Gd-NPs' subcellular localization and uptake, and the cytotoxic effects of the combination, were investigated in 3 cancer cell lines to obtain insights into the involved mechanisms. Results: The optimal [177Lu]Lu-DOTA-trastuzumab activity when combined with Gd-NPs was 5 MBq. Moreover, compared with [177Lu]Lu-DOTA-trastuzumab alone, the strongest therapeutic efficacy (tumor mass reduction) was obtained with 2 injections of 5 mg of Gd-NPs/d (separated by 6 h) at 24 and 72 h after injection of 5 MBq of [177Lu]Lu-DOTA-trastuzumab. In vitro experiments showed that Gd-NPs colocalized with lysosomes and that their radiosensitizing effect was mediated by oxidative stress and inhibited by deferiprone, an iron chelator. Exposure of Gd-NPs to 177Lu increased the Auger electron yield but not the absorbed dose. Conclusion: Targeted radionuclide therapy can be combined with Gd-NPs to increase the therapeutic effect and reduce the injected activities. As Gd-NPs are already used in the clinic, this combination could be a new therapeutic approach for patients with ovarian peritoneal carcinomatosis.
引用
- Garcia-Prada CD, Carmes L, Atis S, et al. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. J Nucl Med. 2023. PMID: 37857502. doi:10.2967/jnumed.123.265418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。